Biotechnology company ImmuneBridge has raised $12m seed financing to advance new natural killer (NK) cell-based immunotherapies. Co-led by global investors Insight Partners and M Ventures, the financing round has also seen participation from Gaingels and One Way Ventures. ImmuneBridge is developing allogeneic NK cell-based immunotherapies to treat solid tumours and hematologic malignancies. According to the company, NK cells represent a platform for allogeneic immunotherapy as they are potent cancer killers, with less risk profile. The company’s orthogonal approach leverages an expansion technology and a diverse clinic-ready source for accelerating the discovery and translation of potent cell therapies. Its expansion technology expands hematopoietic stem cells (HSCs), which are natural NK cells precursors. ImmuneBridge CEO and co-founder Peretz Partensky said: “Cell therapy is a new pillar of medicine and is inextricably human. Cell therapy developers fear donor-to-donor variability, yet we humans are unapologetically diverse in our innate ...
The pharma is handing back two experimental cancer medicines amid a retreat from cell therapy research. GSK has outlined a deal to send two cancer immunotherapies back to biotechnology company Adaptimmune Therapeutics, a move that follows the larger drugmaker’s recent decision to stop investing in cell and gene therapy research. Adaptimmune announced last October that it would regain rights to the two programs, each of which are in development for solid tumors. On Tuesday, the biotech revealed terms of the agreement. It will get about $37 million in cash from GSK, and receive all materials, data and trial sponsorship responsibilities related to the drugs later this year. The agreement will formally end a partnership between GSK and Adaptimmune that dates back to 2014. That year, the two began working on a program called lete-cel, which works by genetically modifying cells to detect NY-ESO, a protein expressed on several ...
[Before the Sartorius buyout, Polyplus had itself been expanding through multiple acquisitions. (Sartorius)] As the biopharma industry struggles with a dire shortage of viral vectors to make cell and gene therapies, contract manufacturers are busy beefing up their capabilities. In the latest example of biopharma’s ongoing investment in cell and gene therapy production, Sartorius has agreed to acquire French company Polyplus for 2.4 billion euros ($2.6 billion), the German CDMO said Friday. The deal gives Sartorius additional know-how in nucleic acid delivery, including transfection reagents and plasmid DNA design, all of which are key elements in the production of viral vectors for building cell and gene therapies. Formed in 2001, Polyplus employs about 270 people in several locations in France, Belgium, the U.S. and China. Before the Sartorius buyout, Polyplus had itself been expanding through M&A deals. In 2021, Polyplus bought Asia-Pacific-focused reagent supplier Biowire. ...
A new test based on gene targeting technology CRISPR could diagnose Covid-19 infections in 45 minutes. It was recently outlined in a paper in the journal Nature Biotechnology.
GlaxoSmithKline (GSK) and Vir Biotechnology have expanded their existing COVID-19 collaboration to include a new research and development agreement, focused on therapies for influenza and other respiratory viruses. The expanded collaboration will give GSK exclusive rights to collaborate with Vir on the development of monoclonal antibodies (mAbs) for the prevention or treatment of influenza. That includes an investigational mAb – VIR-2482 – designed as a universal prophylactic for influenza A, which has completed a Phase I trial. The agreement will also includes next-generation antibodies for the prevention or treatment of influenza during a three-year research period. While GSK will have the exclusive option to co-develop VIR-2482, following Vir’s completion and report of the Phase II trial outcomes, the company will share development costs for all other influenza mAbs. The companies will also conduct two additional research programmes as part of the expanded agreement. The first of these is an expansion ...
A man works in a laboratory of Sinovac Biotech in Beijing on Sept. 24. The Chinese company is developing an experimental coronavirus vaccine. (Thomas Peter/Reuters) By Eva Dou November 18, 2020 at 5:09 p.m. GMT+8 Sinovac Biotech, one of China’s coronavirus vaccine front-runners, published mixed findings from its two first clinical trials Tuesday, raising the stakes in Indonesia, which has already declared plans to roll out Sinovac’s vaccine. While the vaccine appeared to be safe in these early clinical trials, the company reported that it generated lower levels of protective antibodies in the bloodstream compared with those arising in recovered coronavirus patients. In comparison, Moderna and Pfizer, which have separate experimental vaccines, had reported antibody levels on par with or higher than those produced in recovered coronavirus patients. These early results put Sinovac on the back foot to prove its vaccine is effective in ongoing Phase 3 trials. “That is a concern,” ...
President Alberto Fernández confirms Argentina and Mexico will co-produce millions of doses of a coronavirus vaccine developed by scientists at the University of Oxford and Swedish-British pharma firm AstraZeneca. President Alberto Fernández has announced that Argentina and Mexico will co-produce millions of doses of a coronavirus vaccine developed by the AstraZeneca pharmaceutical firm and scientists at the University of Oxford, with it potentially reaching citizens across Latin America in the first quarter of next year. The Peronist leader, speaking at a press conference at the Olivos presidential residence on Wednesday, said that the two countries would be in charge of the “Latin American production” and distribution of a vaccine created by the prestigious British university and Swedish-British pharmaceutical group. Argentina will be in charge of producing “the active substance,” said Fernández, with Mexico finishing “production and packaging.” He said that the country “could be in a position to vaccinate” by the ...
Last month, Russia announced the approval of a COVID-19 vaccine called Sputnik V. This week, President Vladimir Putin announced the approval of a second vaccine, called EpiVacCorona. As with the first, scientists have not yet tested this vaccine in phase 3 trials. The vaccine was developed by scientists at the State Virology and Biotechnology Center, known as Vektor, in Novosibirsk. According to The Moscow Times: “Early trials on 100 volunteers were said to have been successful.” In a televised news conference, Putin explained that researchers had given the vaccine to Deputy Prime Minister Tatyana Golikova and the head of Russia’s consumer safety watchdog, Anna Popova, as part of ongoing trials. During the briefing, they explained that: “Early trials on 100 volunteers were said to have been successful.” As with Sputnik V, experts are likely to view the new vaccine with skepticism. Vaccines must be rigorously investigated before they can be used widely, and ...
(CNN)A Covid-19 vaccine developed by the biotechnology company Moderna in partnership with the National Institutes of Health has been found to induce immune responses in all of the volunteers who received it in a Phase 1 study.
Natural Plant extracts are extensively used in herbal medicine and also cosmetic products. These extracts are safe to take without producing any harmful side-effects. A single plant may contain a number of active principles and hence, it is necessary to get the precise extract as the function of each active principle differs from the other. To get the best extracts, reputed trustworthy natural plant extract suppliers should be made available to the consumers/ physicians. One of the reliable natural plants extracts suppliers/manufacturers that Ddu showcases are the: Yongzhou Huamao Biotechnology Co., Ltd.: This China-based biotechnology firm is a professional supplier of Forage plant crude extract, Cosmetics series products, and Food products. It supplies the Tongkat Ali Eurycomanone extract, Bitter Orange Neohesperidin Extract, Naringin extract, Mulberry leaf flavonoids, Mulberry Leaf Extract 1-DNJ/1-Deoxynojirimycin, Mangosteen polyphenols, and Mangosteen Peel Extract alpha Mangostin. These extracts are in high demand in herbal medicine and cosmetic ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.